Clinical Trial Update: p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pegylated liposomal doxorubicin with APR-246 in platinum-resistant high-grade serous ovarian cancer has completed, and results have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Serous Ovarian Cancer

Drugs mentioned

• APR-246 (eprenetapopt) (eprenetapopt)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Aprea Therapeutics | Conditions: High-grade Serous Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-07-21